Adjuvant Intraperitoneal Floxuridine Added to Chemoradiation for Fully Resected Advanced Stomach Cancer

This study has been completed.
Sponsor:
Collaborator:
Food and Drug Administration (FDA)
Information provided by:
New York University School of Medicine
ClinicalTrials.gov Identifier:
NCT00858338
First received: March 6, 2009
Last updated: February 27, 2012
Last verified: February 2012
  Purpose

This study is to evaluate the efficacy and safety of addition of intraperitoneal (ip) Floxuridine to adjuvant chemoradiation therapy for patients under-going potentially curative stomach resection.


Condition Intervention Phase
Gastric Cancer
Stomach Cancer
Procedure: Potentially curative surgery
Drug: Floxuridine (IP)
Procedure: Adjuvant Chemoradiation therapy
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase-II Study of Adjuvant Intraperitoneal FUDR Treatment Added to Chemoradiation (5-fluorouracil/Leucovorin Plus Total Dose 4500 cGy of External Beam Radiotherapy) in Patients With Fully Resected Locally Advanced Gastric Adenocarcinoma (R0 Resection and at Least D1 Lymph-node Dissection)

Resource links provided by NLM:


Further study details as provided by New York University School of Medicine:

Primary Outcome Measures:
  • toxicity of IP FUDR after surgery prior to chemoradiation [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • overall survival [ Time Frame: up to 10 years ] [ Designated as safety issue: No ]
    every 4 months the first year after treatment; every 6 months 2nd and 3rd year; yearly thereafter up to a total 10 years

  • Time to relapse, disease specific survival [ Time Frame: up to 10 years ] [ Designated as safety issue: No ]
    every 4 months the first year after treatment; every 6 months 2nd and 3rd year; yearly thereafter up to a total 10 years


Enrollment: 28
Study Start Date: December 2002
Study Completion Date: February 2012
Primary Completion Date: March 2007 (Final data collection date for primary outcome measure)
Intervention Details:
    Procedure: Potentially curative surgery

    Surgery:

    Week 1: Potentially curative surgery. If the tumor successfully resected (microscopically disease-free margins, Ro, with regional lymphadenectomy for proper staging), the ip catheter in place.

    Weeks 2-4: Recovery. Then continue to adjuvant IP chemotherapy.

    Drug: Floxuridine (IP)

    Adjuvant IP Chemotherapy:

    week 1: ip Floxuridine 3 gm/day, days 1,2,3. week 2: 1 week without treatment. week 3: ip Floxuridine 3 gm/day protocol days 15,16,17. week 4: 1 week without treatment. Then continue to chemoradiation therapy.

    Other Name: FUDR
    Procedure: Adjuvant Chemoradiation therapy

    Adjuvant Chemoradiation therapy:

    week 1: 5-FU 425 mg/m2/day x 5 days + Leucovorin (LV) 20 mg/m2/day x 5days; weeks 2-4: recovery; weeks 5-9: radiation, 150 cGy x 5 fractions/week x 5 weeks; week 5: 5-FU 400 mg/m2 + LV 20 mg/m2 each day on days 1-4; week 9: 5-FU 400 mg/m2 + LV 20 mg/m2 each day on days 1-3; week 14: 5-FU 425 mg/m2/day x 5 days + Leucovorin (LV) 20 mg/m2/day x 5days; week 19: 5-FU 425 mg/m2/day x 5 days + Leucovorin (LV) 20 mg/m2/day x 5days.

Detailed Description:

Most patients diagnosed with stomach cancer in the US fail to be cured by gastric resection, and most trials of adjuvant chemotherapy do not improve survival rates. However, it has shown that chemo-radiotherapy can substantially increase survival rates after gastric resection in a recent intergroup randomized study (INT 0116) that used adjuvant chemoradiation of 5-fluorouracil (5-FU) and leucovorin concurrently with total dose of 4500 cGy of external-beam radiation treatment (RT) to the abdominal tumor nodal field in patients with resected, locally advanced gastric cancer. However, since the most common recurrences in both arms (surgery only vs. surgery followed by chemoradiation) were regional, typically abdominal carcinomatosis, this may indicate the need for adjuvant ip floxuridine to be added to adjuvant chemoradiation. Our experience for ip floxuridine leads us to hypothesize that the addition of this type of therapy to adjuvant chemoradiation may further increase the cure-rate for patient under-going potentially curative gastric resection. It seems important to convincingly demonstrate the effect of ip floxuridine treatment combined with the chemoradiation regimen. This became the basis for the design of this Phase II study, which will test the toxicity and efficacy of ip floxuridine added to chemo-radiation of the INT 0116 study. The protocol is to be completed in three years, and it may become a springboard for planning and initiation of a pivotal multi-institutional trials.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Eligibility to the protocol is established following complete evaluation specified under 9.2 of the study protocol. This evaluation includes the diagnosis and disease stage. Untreated patients with histologically documented gastric/GEJ carcinoma stages IB-IV (Mo), become eligible.
  • Patients who underwent emergency surgery for indications such as gastrointestinal obstruction, perforation or hemorrhage, or patients with surgery already performed, are eligible as long as the surgery is considered curative (Ro) as specified in section 9.3 of the study protocol.
  • A device for adjuvant ip chemotherapy has to be in situ, placed during the surgery or early (1-3 weeks) thereafter. Time elapsed since the surgery must not exceed 4 weeks.
  • Patient's diagnosis and staging, based on postoperative pathological findings, has to confirm stage IB-IV Mo adenocarcinoma of the stomach or GEJ. Patients and their clinical records must be evaluated by protocol surgical, radiation and medical oncologists, and sections of resected primary tumor and lymph nodes by protocol surgical pathologist.
  • Each patient has to undergo pretreatment evaluation, sign Informed Consent, and be registered.
  • Patients at least 18 years of age with performance status 0-2 (Appendix B of the study protocol).
  • An adequate bone-marrow reserve (segmented neutrophils and bands, at least 1,500/ mmL, thrombocytes at least 100,000 /mmL, hemoglobin at least 9 gm/dL).
  • Preserved liver and renal function (total serum bilirubin <2 mg/dL, SGOT/SGPT not greater than 2.5x the upper limit of normal, alkaline phosphatase not greater than 2.5x the upper limit of normal, BUN not greater than 30 mg/dL, creatinine concentration not greater than 1.5 mg/dL or creatinine clearance >60 mL/min), and negative BHcG in females of reproductive potential, are required.
  • Patient must have evidence of at least unilateral renal function as established by CT scan with contrast or nephrogram. If only one kidney is present, at least two thirds of the functioning kidney must be excluded from any radiation port.
  • The prothrombin time, activated partial thromboplastin time, and thrombin time should be within the range of normal values.
  • All patients and records must be evaluated by a Surgical, Radiation and Medical Oncologists within one month before their entry to this protocol. There should be a reasonable assurance that patient will be available for planned post-treatment follow-up.
  • Each patient must sign the Informed Consent Form.

Exclusion Criteria:

  • Patients who do not meet criteria specified in inclusion criteria, and patients who have received prior RT, chemotherapy or immunotherapy.
  • Patients with another active invasive malignancy. Adequately treated basal cell or squamous cell skin cancer, in-situ cervix cancer, or other cancers the patient has been free for at least 5 years, are acceptable.
  • Patients with active or uncontrolled infection including HIV.
  • Patients with psychiatric disorders that would interfere with their consent.
  • Pregnant and nursing patients. Patients of reproductive age may not participate unless they agree to use an effective contraceptive method.
  • Patients with any other severe concurrent disease, which in judgment of protocol investigators would make the patient inappropriate for this study.
  • Protocol patients who did not receive ip FUDR treatment for complications related to catheter insertion or maintenance. However, these patients may still undergo off-protocol chemoradiation.
  • Patients who did not sign written informed consent.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00858338

Locations
United States, New York
Bellevue Hospital
New York, New York, United States, 10016
NYU Cancer Center
New York, New York, United States, 10016
NYU Tisch Hospital
New York, New York, United States, 10016
Sponsors and Collaborators
New York University School of Medicine
Food and Drug Administration (FDA)
Investigators
Principal Investigator: Franco Muggia, MD New York University School of Medicine
  More Information

Additional Information:
No publications provided

Responsible Party: Franco Muggia, MD, NYU Cancer Institute
ClinicalTrials.gov Identifier: NCT00858338     History of Changes
Obsolete Identifiers: NCT00058916
Other Study ID Numbers: 02-51 (H 10610)
Study First Received: March 6, 2009
Last Updated: February 27, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by New York University School of Medicine:
stomach cancer
gastroesophageal junction cancer
GEJ cancer
intraperitoneal
adjuvant chemoradiation therapy
resection of advanced stomach cancer
locally advanced stomach cancer

Additional relevant MeSH terms:
Stomach Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases
Floxuridine
Leucovorin
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antineoplastic Agents
Therapeutic Uses
Vitamin B Complex
Vitamins
Micronutrients
Growth Substances
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on July 22, 2014